Factor IX concentrate
|Trade names||Haemonine, Benefix, others|
|Other names||Factor IX fraction|
|Main uses||Haemophilia B|
|Side effects||Anxiety, shortness of breath, allergic reactions, nausea, back pain|
Factor IX concentrate, sold under the brand names Haemonine and Benefix among others, is a medication used to treat haemophilia B. Specifically they are used to treat and prevent bleeding. They are given by injection into a vein.
Common side effects include anxiety, shortness of breath, allergic reactions, nausea, and back pain. Other side effects may include angioedema and chest pain. Antibodies that block its ability to work may also develop. It should not be used in disseminated intravascular coagulation. They are manufactured versions of factor IX made from human plasma or by recombinant methods. Risks from versions made from plasma include infection.
Factor IX concentrate became available in the late 1960s, while recombinant versions were approved in 1997. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom 1,000 units of the recombinant or plasma derived versions costs the NHS about £600 as of 2023. Longer acting versions are also available.
- "Factor IX fraction, dried [Specialist drug]". BNF. Archived from the original on 16 September 2023. Retrieved 13 September 2023.
- Konkle, Barbara A (9 February 2023). Hemophilia B. GeneReviews. Archived from the original on 20 October 2019. Retrieved 13 September 2023.
- "Hemophilia: From Plasma to Recombinant Factors". 2008. Archived from the original on 29 May 2023. Retrieved 13 September 2023.
- World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- "Factor IX fraction, dried [Specialist drug] Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 13 September 2023.